2025-11-11T00:11:39-06:00 2024-12-31 471019942 CREATIVE PLANNING TAX LLC 2451 OAKDALE BLVD - STE 204 CORALVILLE IA 52241 990 2024-01-01 205239366 JOHN PAUL II MEDICAL RESEARCH INSTITUTE JOHN 3196653001 2500 CROSSPARK RD E108 CORALVILLE IA 52241 BRANDON MARSH EXECUTIVE DIRECTOR 3196653001 2025-11-03 1 1 BRIAN ARONSON CPA P01425251 3193543000 2025-10-28 2024 2025-03-06 01:10:19Z BRANDON MARSH 2500 CROSSPARK RD E108 CORALVILLE IA 52241 206611 0 X WWW.JP2MRI.ORG X 2006 IA ADVOCATES FOR MEDICAL RESEARCH THAT RECOGNIZES THE DIGNITY OF HUMAN LIFE. 2 2 4 6 0 0 346818 206355 0 0 270 256 0 0 347088 206611 0 20000 0 0 241877 99936 0 0 908 257834 141104 499711 261040 -152623 -54429 327693 253344 140120 120200 187573 133144 X THE JOHN PAUL II MEDICAL RESEARCH INSTITUTE (JP2MRI) SEEKS TO FIND CURES AND THERAPIES EXCLUSIVELY USING A VARIETY OF ADULT STEM CELLS AND INDUCED PLURIPOTENT STEM CELLS. THE INSTITUTE DOES NOT ENGAGE IN EMBRYONIC STEM CELL RESEARCH OF ANY KIND. JP2MRI DEVELOPS PRECLINICAL RESEARCH TECHNOLOGIES THAT WILL BROADLY ADVANCE DRUG DISCOVERY AND REGENERATIVE MEDICINE FOR MANY DISEASES. IN ADDITION, THE INSTITUTE WILL ENGAGE IN EDUCATIONAL OUTREACH TO INCREASE THE NUMBER OF SCIENTISTS AND FUTURE MEDICAL PRACTITIONERS WHO WILL WORK WITH ADULT STEM CELLS, ALWAYS WITH AN EMPHASIS ON MEDICAL BIOETHICS THAT IS CONSISTENT WITH THE DIGNITY OF HUMAN LIFE. 0 0 154650 20000 TO DEVELOP A COLLABORATIVE BASIC AND CLINICAL RESEARCH PROGRAM IN OUR FOUR CORE RESEARCH AREAS: CANCER, NEURODEGENERATIVE DISEASES, RARE DISEASES, AND ADULT STEM CELL THERAPIES. IN 2024, JP2MRI CONTINUED OUR RESEARCH EFFORTS INTO DEVELOPING AN IMMORTALIZED STEM CELL LINE TO REPLACE THE ABORTED FETAL CELL LINES BEING USED IN RESEARCH PHARMACEUTICAL APPLICATIONS. THE INSTITUTE ALSO CONTINUED ITS EFFORTS INTO DEVELOPING A SAFER AND MORE ROBUST CORONAVIRUS VACCINE UTILIZING A TRADITIONAL NON-MRNA BASED APPROACH THAT IS FREE OF ABORTED FETAL TISSUE DURING DEVELOPMENT AND TESTING. 154650 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 2 0 1 4 1 0 0 0 0 0 0 0 0 0 0 0 0 X 2 2 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 0 0 0 0 X X BRANDON MARSH 3196653001 2500 CROSSPARK RD E108 CORALVILLE IA 52241 DR ALAN MOY PRESIDENT (THRU 04/2024) 5.00 X X 0 0 0 JAY KAMATH VP/SECRETARY (THRU 11/2024) 5.00 X X 73966 0 0 JEANNE MOY DIRECTOR 0.25 X 0 0 0 FATHER ISAAC DOUCETTE DIRECTOR 0.25 X 0 0 0 DR JAMES BECKER DIRECTOR (THRU 8/2024) 0.25 X 0 0 0 DR MARTIN BEDNAR DIRECTOR (THRU 8/2024) 0.25 X 0 0 0 73966 0 0 0 0 0 0 0 206355 206355 256 256 206611 0 0 256 20000 20000 73966 19301 54665 10451 10451 9172 1391 7781 6347 3993 2354 35 35 6410 6410 610 610 298 298 15639 15639 32466 32466 13800 13800 7715 7715 893 893 RESEARCH & DEVELOPMENT 46285 46285 BAD DEBT 12003 12003 SUBSCRIPTION AND DUES 1045 1045 3905 3905 261040 154650 105482 908 272929 234766 35476 0 179866 161288 19288 18578 327693 253344 9000 977 3125 3248 127995 115975 140120 120200 X 0 0 0 0 187573 133144 187573 133144 327693 253344 -54429 0 X 0 0 0 X 253162 775994 464437 346818 206355 2046766 253162 775994 464437 346818 206355 2046766 397446 1649320 86 196 358 270 256 1166 8036 4953 12989 2060921 0.80030 0.78990 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 179866 161288 18578 18578 0 CELLULAR ENGINEERING TECHNOLOGIES 2500 CROSSPARK DR CORALVILLE IA 52241 421499806 20000 0 RESEARCH GRANT 0 1 JEANNE MOY OFFICER/DIRECTOR OPERATING EXPENSES X 3818 3248 0 1 1 3248 FORM 990, PART VI, SECTION A, LINE 2 DR. ALAN MOY AND JEANNE MOY - FAMILY RELATIONSHIP FORM 990, PART VI, SECTION B, LINE 11B FORM 990 IS PROVIDED TO THE BOARD OF DIRECTORS, WITH THE OPTION TO REVIEW AND PROVIDE FEEDBACK, PRIOR TO FILING WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C BOARD MEMBERS ARE REQUIRED TO SUBMIT ANNUAL SURVEYS DISCLOSING ANY CONFLICTS OF INTEREST. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST FOR THE SAME PERIOD OF DISCLOSURE AS SET FORTH IN SECTION 6104(D).